Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMG324 vs Ranibizumab in Neovascular AMD
NCT02398500Phase 2Terminated
- Sponsor
- Alcon Inc.
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LMG324 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Alcon Inc. Primary endpoint: Mean change from baseline in best corrected visual acuity at Day 85. Started Jul 2015; status: terminated.
02
Drugs
LMG324
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02398500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398500.